The science of Qelbree

A different approach to ADHD treatment

The way Qelbree works to treat ADHD is unclear but is thought to involve its ability to increase the amount of the chemical messenger norepinephrine in the brain.

Qelbree is known to interact with norepinephrine and the chemical messenger serotonin. Qelbree is the only ADHD treatment shown to interact with serotonin where it binds at 5-HT_2C.

Two important checmicals of the brain: Norepinephrine and Serotonin 5-HT₂C

5+ years of experience

FDA approved in 2021 for patients 6-17 years old with ADHD, and in 2022 for adults with ADHD, Qelbree brings over 5 years of real-world experience.

Learn more about ADHD

Learn more about the science behind ADHD, chemical messengers, and how they may affect symptoms of ADHD.

About ADHD

Learn more about Qelbree

In adults

In children 6-17 years

Benefits of Qelbree as a non-stimulant

INDICATION

Qelbree^® (viloxazine extended-release capsules) is a prescription medicine used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children 6 years and older.

IMPORTANT SAFETY INFORMATION
Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment [read more] or when the dose is changed. Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

IMPORTANT SAFETY INFORMATION
Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment or when the dose is changed. [read more] Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

You should not take Qelbree if you or your child:
Take a medicine for depression called a monoamine oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past 14 days. Also, you or your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.

Qelbree can increase blood pressure and heart rate. Your or your child’s doctor will monitor these vital signs.

Qelbree may cause manic episodes in patients with bipolar disorder. Tell your doctor if you or your child show any signs of mania.

Do not drive or operate heavy machinery until you know how Qelbree will affect you or your child. Qelbree may cause you or your child to feel sleepy or tired.

The most common side effects of Qelbree in patients 6 to 17 years are sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability, and in adults, insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation. These are not all the possible side effects of Qelbree.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Medication Guide, including Boxed Warning.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE